News from Zyme and the companies we work with.

January 21, 20

Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio

Cell line to be used to support research and development of biotherapeutics across therapeutic areas  Cambridge, UK, 21 January 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene … Continue reading →

January 21, 20

Avacta Group plc appoints Paul Fry as Non-Executive Director

Highly experienced pharmaceutical and biotech professional joins Avacta’s Board Cambridge, UK, 21 January 2020: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce the appointment of Paul Fry as Non-Executive Director with effect … Continue reading →

January 21, 20

PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical

PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka’s therapeutics discovery programmes Programmes to initially focus on gene therapy applications of identified targets Cambridge, UK, 21 January 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging … Continue reading →

January 17, 20

ERS Genomics provides comment on EPO Technical Board of Appeal decision upholding the revocation of Broad Institute CRISPR patent  

DUBLIN, Ireland, 17 January 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier, announced that yesterday the European Patent Office’s (EPO) Technical Board of Appeal (Board) upheld … Continue reading →

January 14, 20

Horizon Discovery to provide access to novel base editing technology

Next-generation gene editing system has applications in development of cell and gene therapies Base editing builds on CRISPR offering and will expand Horizon’s research tools and services Horizon seeks partners to assess and shape platform development  Cambridge, UK, 14 January … Continue reading →

January 13, 20

Horizon Discovery signs collaboration and license agreement with Mammoth Biosciences

Aims to develop the next generation of engineered CHO cell lines, to improve production of biotherapeutics Bioproduction is a key business unit within Horizon, this agreement underlines strategy to focus on core markets Cambridge, UK, 13 January 2020: Horizon Discovery Group … Continue reading →

January 13, 20

Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform

CAMBRIDGE, UK, and LEUVEN, Belgium, 13 January 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec, a world-leading research and innovation hub … Continue reading →

January 13, 20

ERS Genomics licenses CRISPR gene editing technology to Daiichi Sankyo to support internal research and development  

DUBLIN, Ireland, 13 January 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical … Continue reading →

January 8, 20

New Scientific Advisory Board adds 70 years of R&D expertise to Turbine’s simulation-first drug discovery mission

Dr. Annalisa Jenkins, Dr. Mihriban Tuna and Dr. Alan Barge appointed to guide Turbine’s scientific strategy Turbine aims to use simulation technology to transform trial-and-error approach to cancer drug discovery Budapest, Hungary, 08 January 2020: Turbine, a simulation-first drug discovery … Continue reading →

January 8, 20

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients

“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance Co-authored by researchers from University … Continue reading →